Publications by authors named "Takayoshi Demura"
Previous studies have indicated a possible relationship between increased prostate volume (PV) and decreased biopsy yield, although the mechanism involved is unclear. We evaluated 1650 patients who underwent template biopsy. The distribution of 993 cancer lesions in 302 prostatectomy specimens was compared with the biopsy data to determine whether each lesion was detected.
View Article and Find Full Text PDFObjectives: The present study was carried out to analyze pathological features of prostatectomy specimens performed at different timing and trigger during active surveillance.
Methods: One hundred and thirty-four patients that fit a selection condition similar to the so-called Hopkins' criteria were enrolled into the present study between January 2002 and December 2003. Patients were recommended to start curable treatment when they showed prostate-specific antigen-doubling time of 2 years or shorter or pathological progression at 1-year re-biopsy.
Background And Aims: The aim of the present phase II study was to evaluate the efficacy of combination chemotherapy of paclitaxel, ifosfamide, and nedaplatin (PIN regimen) in patients with recurrent urothelial cancer who had been treated with cisplatin-based chemotherapy.
Patients/methods: Eligible patients were those with histologically confirmed urothelial cancer who had progressed or relapsed after cisplatin-based chemotherapy. The PIN regimen consisted of paclitaxel 175 mg/m(2) on day 1; ifosfamide 4.
Background: The authors performed extensive transperineal ultrasound-guided template prostate biopsies to investigate carcinoma core distribution.
Methods: Between August 2000 and May 2004, 371 men underwent template biopsies. Three hundred twelve patients had not undergone a previous biopsy (first group) and 59 had undergone previous transrectal sextant biopsies (repeat group).
Article Synopsis
- The TIN regimen, consisting of ifosfamide, paclitaxel, and nedaplatin, was given to metastatic urothelial cancer patients who had prior platinum-based treatments, with a high response rate of 91.6%.
- Four patients continued with maintenance therapy for an extended period, contributing to a median overall survival of 10.5 months and a one-year overall survival rate of 53.5%.
- The treatment had significant hematologic side effects, with all patients experiencing neutropenia, but none had to stop due to complications, indicating it was well-tolerated despite the risks.
Background: We performed extensive transperineal ultrasound guided template prostate biopsy and evaluated cancer core distribution.
Methods: From August 2000 to May 2002, 113 men with prostate specific antigen levels between 4.0 and 10.